PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography

Description

The PD-1 and PD-L1 inhibitor market is estimated to be valued at USD 52.51 Bn in 2024 and is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 52.51 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	18.30%	2030/2031 Value Projection:	US$ 170.01 Bn

PD-1 and PD-L1 Inhibitor Market Share (%), By Region, 2024

PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.

Market Dynamics:

The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.

Key Features of the Study:

This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.

Market Segmentation

Type of Inhibitor:
- PD-1 Inhibitors
- PD-L1 Inhibitors
Cancer Type:
- Kidney
- Melanoma
- Bladder
- Non-small Cell Lung Cancer
- Liver
- Head & neck
- Others
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- Merck & Co.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD

Product Code: CMI173

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
PD-1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
PD-L1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Kidney
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Bladder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Non-small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Head & Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2019-2031, (US$ Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi AG
F. Hoffmann-La Roche AG
Merck & Co.
Bristol-Myers Squibb Company
Regeneron Pharmaceuticals Inc.
GSK plc
Ono Pharmaceutical Co., Ltd.
Eli Lilly and Company
BeiGene LTD

10. Analyst View

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us and Sales Contact

PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography

Description

Table of Contents

Market Dynamics:

Key Features of the Study:

Market Segmentation

Table of Contents:

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2019-2031, (US$ Bn)